VACCINE PHARMACEUTICAL COMPOSITION FOR SUPPRESSING APOPTOSIS OF CTL OR INHIBITING SUPPRESSION OF INDUCTION OF CTL

Abstract

The present invention aims to provide a vaccine pharmaceutical composition that can be universally used for induction of cellular immunity to various antigens and that exerts a high inducing effect. The present invention relates to a vaccine pharmaceutical composition that suppresses apoptosis of CTL or inhibits suppression of induction of CTL.

Claims

1. A vaccine pharmaceutical composition for administration containing an antigen to induce cellular immunity, wherein the vaccine pharmaceutical composition suppresses apoptosis of CTL or inhibits suppression of induction of CTL.

2. The vaccine pharmaceutical composition according to claim 1, wherein the expression rate of PD-1 receptor in antigen-specific CD8-positive T cells in an animal model for immunological evaluation administered with the vaccine pharmaceutical composition is 40% or less.

3. The vaccine pharmaceutical composition according to claim 1, wherein the rate of induction of apoptosis of antigen-specific CD8-positive T cells in an animal model for immunological evaluation administered with the vaccine pharmaceutical composition is 30% or less.

4. The vaccine pharmaceutical composition according to claim 1, wherein an antigen-specific Th1/Treg ratio in an animal model for immunological evaluation administered with the vaccine pharmaceutical composition is controlled.

5. The vaccine pharmaceutical composition according to claim 1, further containing a first cellular immunity induction promoter.

6. The vaccine pharmaceutical composition according to claim 1, which is administered in multiple doses.

7. The vaccine pharmaceutical composition according to claim 5, wherein the first cellular immunity induction promoter is at least one of a TLR ligand or a cyclooxygenase inhibitor.

8. The vaccine pharmaceutical composition according to claim 1, further containing a second cellular immunity induction promoter which is a helper peptide.

9. A method of inducing cellular immunity in a subject comprising: administering to the subject a vaccine pharmaceutical composition comprising an antigen that induces cellular immunity on administration, wherein the vaccine pharmaceutical composition suppresses apoptosis of CTL or inhibits suppression of induction of CTL on administration.

10. The method of inducing cellular immunity according to claim 9, wherein the vaccine pharmaceutical composition is one that produces an expression rate of PD-1 receptor in antigen-specific CD8-positive T cells of 40% or less when administered to an animal model for immunological evaluation.

11. The method of inducing cellular immunity according to claim 9, wherein the vaccine pharmaceutical composition is one that produces an induction rate of apoptosis of antigen-specific CD8-positive T cells of 30% or less when administered to an animal model for immunological evaluation.

12. The method of inducing cellular immunity according to claim 9, wherein the vaccine pharmaceutical composition is one that produces a controlled antigen-specific Th1/Treg ratio when administered to an animal model for immunological evaluation.

13. The method of inducing cellular immunity according to claim 9, wherein the vaccine pharmaceutical composition further comprises a first cellular immunity induction promoter.

14. The method of inducing cellular immunity according to claim 9, comprising administering the vaccine pharmaceutical composition in multiple doses.

15. The method of inducing cellular immunity according to claim 13, wherein the first cellular immunity induction promoter is at least one of a TLR ligand or a cyclooxygenase inhibitor.

16. The method of inducing cellular immunity according to claim 13, wherein the vaccine pharmaceutical composition further comprises a second cellular immunity induction promoter, which is a helper peptide.

Description

BRIEF DESCRIPTION OF DRAWINGS

[0382] FIG. 1 shows diagrams showing expression of PD-1 receptor in antigen-specific CD8-positive T cells resulting from subcutaneous administration of injections prepared in Example 3 and Comparative Example 6.

DESCRIPTION OF EMBODIMENTS

[0383] The present invention will be described below in further detail with reference to examples, but the present invention is not limited to these examples.

EXAMPLES 1, 2

Preparation of Cream for Transdermal Administration

[0384] A cream for transdermal administration was prepared according to the formulation shown in Table 2 below. Specifically, an antigen peptide, a first cellular immunity induction promoter, a second cellular immunity induction promoter (helper peptide), 15% by weight of dimethylsulfoxide (DMSO), which are described below, were mixed in amounts as specified in Table 2. A base (base cream) was added to the mixture to obtain a total weight of 100% by weight, followed by mixing. Thus, a cream for transdermal administration was prepared. The base cream used was prepared by mixing the materials shown in Table 1 in amounts as specified.

[0385] A PET film/PET nonwoven fabric laminate (area: 0.7 cm.sup.2) was attached to the center of an adhesive tape for fixing, with the PET film side on the tape side, whereby a complex base was provided. The cream for transdermal administration (4 mg) was applied to a nonwoven fabric portion of the complex base. This was used as an administration sample in an immunity test.

TABLE-US-00002 TABLE 1 Additive Amount White Vaseline 60.7% by weight  Sorbitan monostearate 0.7% by weight Isostearic acid 12.0% by weight  Benzyl alcohol 2.4% by weight Cetanol 2.4% by weight Stearyl alcohol 3.5% by weight Polysorbate 60 3.5% by weight Concentrated glycerin 2.4% by weight Purified water 12.4% by weight 

[0386] White Vaseline, sorbitan monostearate isostearic acid, benzyl alcohol, stearyl alcohol, Polysorbate 60, concentrated glycerin, and dimethylsulfoxide (DMSO) were purchased from Wako Pure Chemical Industries, Ltd. Cetanol was purchased from Tokyo Chemical Industry Co., Ltd. Imiquimod (IMQ) as the first cellular immunity induction promoter was purchased from Ferrer, and loxoprofen sodium (LOX) was purchased from Yoshindo Inc. PADRE was used as the second cellular immunity induction promoter.

[0387] Note that OVA peptide is an amino acid peptide having a sequence of SIINFEKL (Ser Ile Ile Asn Phe Glu Lys Leu) (SEQ ID No: 16).

<Evaluation 1>

[0388] The creams for transdermal administration prepared in the examples were evaluated as follows.

Mouse Immunity Test 1 (Cream)

[0389] According to the procedure described below, the cream for transdermal administration was used to carry out a mouse immunity test using an animal model for immunological evaluation. Subsequently, the level of induction of antigen-specific cellular immunity was evaluated by ELISPOT assay.

[0390] Specifically, the back of a mouse was shaved, and the mouse was reared for a while to recover from skin damage caused by shaving. Then, the sample was administered to the skin on the back of the mouse for a certain period of time, and removed. The mouse was reared for a certain period of days, and the level of induction of antigen-specific cellular immunity was evaluated. The spleen was extracted a predetermined days after the last administration, and a spleen cell suspension was prepared. Spleen cells (1×10.sup.6 cells/well) and the antigen peptide (100 μM) in a culture medium were poured into wells of an ELISPOT plate on which anti-mouse IFN-γ-antibody was immobilized. The spleen cells were co-cultured with the antigen peptide for 20 hours under culture conditions of 37° C. and 5% CO.sub.2. The number of IFN-γ-producing cell spots (number of spots/1×10.sup.6 cells) was evaluated by ELISPOT assay. The cream was administered in a dose of 4 mg every time at a frequency of (24 hr/week)×one time or (24 hr/week)×two times. The spleen was extracted 6 days after the last administration. The “(24 hr/week)” means that transdermal administration was carried out continuously for 24 hours per week.

[0391] Further, the number of IFN-γ-producing cell spots from the second immunization relative to the number of IFN-γ-producing cell spots from the first immunization was measured as a ratio of increase or decrease in IFN-γ-producing cells. Table 2 shows the results.

Examples 3 to 5, Comparative Examples 1 to 6

Preparation of Injection for Subcutaneous Administration

[0392] An injection for subcutaneous administration was prepared according to the formulation shown in Table 2 below. This was used as an administration sample in an immunity test. Specifically, the antigen, the first cellular immunity induction promoter, and the second cellular immunity induction promoter (helper peptide) were weighed and mixed in amounts as specified in Table 2, and saline was added to the mixture to obtain a total weight of 1000 μL, followed by mixing with a homogenizer. Thus, an injection for subcutaneous administration was prepared.

<Evaluation 2>

[0393] The injections for subcutaneous administration prepared in the examples were evaluated as follows.

Mouse Immunity Test 2 (Injection)

[0394] According to the following procedure, the injection for subcutaneous administration was used to carry out a mouse immunity test using an animal model for immunological evaluation.

[0395] Specifically, a mouse immunity test was carried out as in the mouse immunity test 1 described above. The injection was subcutaneously administered in a dose of 50 μL at a frequency of one or two times. The spleen was extracted 6 days after the last administration. Table 2 shows the results.

Mouse Skin Permeability Test (Cream)

[0396] OVA peptide, imiquimod (IMQ), and loxoprofen (LOX) were tested for skin permeability using a Franz type diffusion cell. The skin isolated from the back of a mouse that had been shaved in advance was mounted on the Franz type di diffusion cell (application area: 4.91 cm.sup.2) in which phosphate buffer (pH 7.4 isotonic buffer) at 37° C. was circulated. A preparation having a size of 0.7 cm.sup.2 of was attached to the skin mounted on the Franz type diffusion cell, and a sample in the cell was collected 24 hours after the administration. The collected sample was subjected to a high performance liquid chromatograph-tandem mass spectrometer, and the amount of OVA peptide which permeated the skin 24 hours after the administration (amount of permeated OVA peptide, μg/cm.sup.2/24 hr) and the amount of LOX (amount of permeated LOX, μg/cm.sup.2/24 hr) were calculated from a calibration curve which had been determined in advance. Table 2 shows the results.

Weight Ratio of the First Cellular Immunity Induction Promoter to the Antigen

[0397] The weight ratio of the first cellular immunity induction promoter to the antigen in the injection administered was calculated from the dose injected into the immunized mouse. In the case of transdermal administration, none of the transdermally administered antigen and the transdermally administered first cellular immunity induction promoter are present in the skin. Since the preparation is removed 24 hours after the transdermal administration, the amounts of the antigen and the first cellular immunity induction promoter which permeated the skin were measured 24 hours after the mouse skin permeability test described above, and the weight ratio of the administered first cellular immunity induction promoter to the administered antigen was calculated, Table 2 shows the results.

[0398] Method for testing the expression rate of PD-1 receptor in antigen-specific CD8-positive T cells

[0399] The expression rate of PD-1 receptor in antigen-specific CD3-positive T cells was evaluated by FACS (Becton, Dickinson and Company, Japan). A mouse immunity test was carried out in the same manner as in the mouse immunity test 1. The cream was administered in a dose of 4 mg, and the injection was administered in a dose of 50 μL, at a frequency of (24 hr/week)×two times. The spleen was extracted 3 days after the last administration. The “(24 hr/week)” means that transdermal administration was carried out continuously for 24 hours per week.

[0400] Further, the spleen cells were reacted with anti-CD8-FITC and tetramer-SIINFEKL-PE to detect OVA peptide-specific CD8-positive T cells, and reacted with anti-CD279 (PD-1 receptor)-APC to detect PD-1 receptor, and the expression rate was measured by FACS. Evaluation was carried out as follows: first, CD8-positive T cells and tetramer-positive (both positive) cells were gated; the percentage of PD-1 receptor-positive cells in these cells was measured, and the expression rate of PD-1 receptor in OVA peptide-specific CD8-positive T cells was evaluated. FIG. 1 shows representative results, and Table 2 shows all the results, Anti-CD8-FITC and tetramer-SIINFEKL-PE were purchased from MBL, and anti-CD279 (PD-1 receptor)-APC was purchased from Biolegend.

[0401] In the case of evaluating the expression rate of PD-1 receptor in antigen-specific CD8-positive T cells for antigens other than OVA peptide, the expression rate is measured using antigen-specific tetramer which is prepared or purchased instead of tetramer-SIINFEKL-PE.

[0402] In Examples 1 to 5, CTL was enhanced by two-time administration, and the expression rate of PD-1 receptor in antigen-specific CD8-positive T cells was low. In contrast, the opposite behavior was observed in Comparative Examples 1 to 6. This shows that the pharmaceutical composition can suppress expression of PD-1 receptor, and can enhance antigen-specific CD8-positive T cells in continuous multiple dose administration. In addition, the expression level of PD-4 receptor was low when the weight ratio of the administered first cellular immunity induction promoter was 150 parts by weight or more per part by weight the administered antigen. Table 2 below shows the test results.

[0403] Method for testing the rate of induction of apoptosis of antigen-specific CD8-positive T cells

[0404] The rate of induction of apoptosis of antigen-specific CD8-positive T cells was evaluated by FACS. A mouse immunity test was carried out in the same manner as in the mouse immunity test 1. The cream was administered in a dose of 4 mg, and the injection was administered in a dose of 50 μL, at a frequency of (24 hr/week)×two times. The spleen was extracted 3 days after the last administration. The “(24 hr/week)” means that transdermal administration was carried out continuously for 24 hours per week.

[0405] Further, the spleen cells were reacted with anti-CD8-FITC and tetramer-SIINFEKL-PE to detect OVA peptide-specific CD8-positive T cells, and reacted with APC-Annexin V to detect apoptosis, and the expression rate was measured by FACS. Evaluation was carried out as follows: first, CD8 positive T cells and tetramer positive (both positive) cells were gated; the percentage of Annexin V positive cells in these cells was measured; and the rate of induction of apoptosis of OVA peptide-specific CD8-positive T cells was evaluated. FIG. 1 shows representative results, and Table 2 shows all the results. Anti-CD8-FITC and tetramer-SIINFEKL-PE were purchased from MBL, and APC-Annexin V was purchased from Biolegend.

[0406] In the case of evaluating the rate of induction of apoptosis of antigen-specific CD8-positive T cells for antigens other than OVA peptide, the expression rate is measured using antigen-specific tetramer that is prepared or purchased instead of tetramer-SIINFEKL-PE.

[0407] In Examples 1 to 5, CTL was enhanced by two-time administration, and the rate of induction of apoptosis of antigen-specific CD8-positive T cells was low. In contrast, the opposite behavior was observed in Comparative Examples 1 to 6. This shows that the vaccine pharmaceutical composition of the present invention can suppress induction of apoptosis of CTL, and can enhance antigen-specific CD8-positive T cells in continuous multiple dose administration. In addition, the induction of apoptosis was low when the weight ratio of the administered first cellular immunity induction promoter was 150 parts by weight or more per part by weight of the administered antigen. Table 2 below show the test results.

[0408] Creams for transdermal administration, injections for intradermal administration, and injections for subcutaneous administration were prepared according to the formulations shown in Tables 3, 4, 5, and 6 below, in the same manner as in Examples 1 to 5 and Comparative Examples 1 to 6. In Table 3 below, the helper peptide was OVA class II peptide (sequence Ile Ser Gln Ala Val His Ala Ala His Ala Glu Ile Asn Glu Ala Gly Arg (SEQ ID No: 17)). In Table 4 below, the cancer antigen peptide was PR1 peptide. In Table 5 below, the cancer antigen peptide was HER2/neu_E75 peptide. In Table 6 below, the cancer antigen peptide was survivin 2B peptide.

[0409] In Examples 6 to 16 in Tables 3 to 6 below, according to the results of the method for testing the expression rate of PD-1 receptor in antigen-specific CD8-positive T cells, CTL was enhanced by two-time administration, and the expression rate of PD-1 receptor in antigen-specific CD8-positive T cells was decreased. In contrast, the opposite behavior was observed in Comparative Examples 7 to 21. Thus, the pharmaceutical composition can suppress expression of PD-1 receptor, and can enhance antigen-specific CD8-positive T cells in continuous multiple dose administration. In addition, the expression level of PD-1 receptor decreases when the weight ratio of the administered first cellular immunity induction promoter was 150 parts by weight or more per part by weight of the administered antigen.

[0410] In addition, in Examples 6 to 16 in Tables 3 to 6 below, according to the results of the method for testing the rate of induction of apoptosis of antigen-specific CD8-positive T cells, CTL was enhanced by two-time administration in the examples, and the rate of induction of apoptosis of antigen-specific CD8-positive T cells was decreased. In contrast, the opposite behavior was observed in Comparative Examples 7 to 21. Thus, the pharmaceutical composition can suppress induction of apoptosis of CTL, and can enhance antigen-specific CD8-positive T cells in continuous multiple dose administration. In addition, the induction of apoptosis decreases when the weight ratio of the administered first cellular immunity induction promoter to the administered antigen was 150 parts by weight or more.

(Method for Testing the Antigen-Specific Th1/Treg Ratio)

[0411] The antigen-specific Th1/Treg ratio can be measured according to the procedure described below. For example, in the case of OVA antigen, a cream for transdermal administration and an injection for intradermal administration are prepared according to the formulation shown in Table 3 below, and evaluation can be made by carrying out an immunity test.

[0412] The Th1/Treg ratio is evaluated by FADS. A mouse immunity test is carried out in the same manner as in the mouse immunity test 1. The cream is administered in a dose of 4 mg, and the injection is intradermally administered in a dose of 50 μL, at a frequency of (1 to 3 times/week)×multiple times (2 to 5 times). The spleen is extracted 6 days or an appropriate number of days after the last administration.

[0413] The method for measuring the antigen-specific Th1/Treg ratio is as follows: in the case of Th1 cells, spleen cells are reacted with anti-CD4-FITC, OVA class II peptide-specific tetramer (or tetramer-ISQAVHAAHAEINEAGR-PE in the case of OVA antigen) and APC-CD183, and cel that are CD4 positive and tetramer positive (both positive) are gated by FACS. Then, the percentage of CD183 positive cells in these cells is measured, and the number of OVA class II peptide-specific Th1 cells is calculated. Treg cells are isolated from spleen cells using Dynabeads (DYNAL). Further, Treg cells are labeled with OVA class II peptide-specific tetramer (or tetramer-ISQAVHAAHAEINEAGR-PE in the case of OVA antigen), and the number of OVA class II peptide-specific Treg cells is calculated. Alternatively, Treg cells are labeled with anti-CD4-FITC, anti-FoxP3-APC, and tetramer-ISQAVHAAHAEINEAGR-PE), and the number of OVA class II peptide-specific Treg cells is calculated. The ratio of Th1 cells to Treg cells is calculated based on these cell counts. Anti-CD4-FITC and tetramer-ISQAVHAAHAEINEAGR-PE are purchased from MBL; aPC-CD183, anti-CD4-FITC, and anti-FoxP3-APC are purchased from Biolegend; and Dynabeads mouse CD4.sup.+CD25.sup.+Treg cells are purchased from invitrogen. In the case of an antigen other than OVA, antigen-specific tetramer which is prepared or purchased is used.

TABLE-US-00003 TABLE 2 First Second cellular cellular immunity immunity induction promoter induction (other than Antigen peptide promoter helper peptide) Dose (helper peptide) Dose % by (ug) % by % by (ug) Route Base Kind weight (A) Kind weight Kind weight (B) Example 1 Transdermal Cream OVA peptide 5 200 PADRE 1 IMQ 3 120 Example 2 Cream OVA peptide 5 200 PADRE 1 LOX 3 120 Example 3 Injection Saline/Montanide OVA peptide 0.00008 0.04 PADRE 0.05 IMQ 0.05 25 Comparative (subcutaneous) Saline/Montanide OVA peptide 0.0004 0.2 PADRE 0.05 IMQ 0.05 25 Example 1 Comparative Saline/Montanide OVA peptide 0.002 1 PADRE 0.05 IMQ 0.05 25 Example 2 Comparative Saline/Montanide OVA peptide 0.2 100 PADRE 0.05 IMQ 0.05 25 Example 3 Example 4 Saline/Montanide OVA peptide 0.000016 0.008 PADRE 0.05 LOX 0.05 25 Example 5 Saline/Montanide OVA peptide 0.00008 0.04 PADRE 0.05 LOX 0.05 25 Comparative Saline/Montanide OVA peptide 0.0004 0.2 PADRE 0.05 LOX 0.05 25 Example 4 Comparative Saline/Montanide OVA peptide 0.002 1 PADRE 0.05 LOX 0.05 25 Example 5 Comparative Saline/Montanide OVA peptide 0.2 100 PADRE 0.06 LOX 0.05 25 Example 6 Weight Increase/ Percentage ratio of decrease of Results of skin promoter rate of expression permeability test to Number of CTL [%] level of OVA peptide IMQ LOX angiten IFN-γ- due to PD-1 Percentage Skin Skin Skin [%] producing multiple in CD8- of permeation permeation permeation {Cream: cell spots dose positive Annexin amount amount amount (D) or After 1st After 2nd admini- and V + in (C) (D) (E) (E)/(C)} Immuni- Immuni- stration tetramer- CD8* and [ug/cm.sup.2/ [ug/cm.sup.2/ [ug/cm.sup.2/ {Injection: zation zation {(G)/(F) * positive tetramer + 24 h] 24 h] 24 h] (B)/(A)} (F) (G) 100} cells [%] cells [%] Example 1 0.012 2 — 167 422 431 102.1 20 26 Example 2 0.015 — 40 2867 321 340 106.1 22 22 Example 3 — — — 625 832 745 116 24 14 Comparative — — — 125 834 559 67 48 31 Example 1 Comparative — — — 25 1032 462 45 42 32 Example 2 Comparative — — — 0.3 971 561 58 70 40 Example 3 Example 4 — — — 3125 24 109 447 25 22 Example 5 — — — 625 64 135 211 29 25 Comparative — — — 125 303 149 49 44 38 Example 4 Comparative — — — 25 446 100 22 42 36 Example 5 Comparative — — — 0.3 291 163 56 52 45 Example 6

TABLE-US-00004 TABLE 3 Second cellular immunity induction promoter Antigen peptide (helper Dose peptide) % by (ug) % by Route Base Kind weight (A) Kind weight Example 6 Transdermal Cream OVA peptide 5 200 OVA class II 1 peptide Example 7 Cream OVA peptide 5 200 OVA class II 1 peptide Example 8 Injection Saline/Montanide OVA peptide 0.00008 0.04 OVA class II 0.1 (subcutaneous) peptide Comparative Saline/Montanide OVA peptide 0.0004 0.2 OVA class II 0.1 Example 7 peptide Comparative Saline/Montanide OVA peptide 0.002 1 OVA class II 0.1 Example 8 peptide Comparative Saline/Montanide OVA peptide 0.2 100 OVA class II 0.1 Example 9 peptide Example 9 Saline/Montanide OVA peptide 0.000016 0.008 OVA class II 0.1 peptide Example 10 Saline/Montanide OVA peptide 0.00008 0.04 OVA class II 0.1 peptide Comparative Saline/Montanide OVA peptide 0.0004 0.2 OVA class II 0.1 Example 10 peptide Comparative Saline/Montanide OVA peptide 0.002 1 OVA class II 0.1 Example 11 peptide Comparative Saline/Montanide OVA peptide 0.2 100 OVA class II 0.1 Example 12 peptide Weight First Results of skin ratio of cellular permeability test promoter immunity OVA to induction peptide IMQ LOX angiten promoter Skin Skin Skin [%] (other than permeation permeation permeation {Cream: helper peptide) amount amount amount (D) or Dose (C) (D) (E)/(C)} % by (ug) [ug/cm.sup.2/ [ug/cm.sup.2/ [ug/cm.sup.2/ {Injection: Kind weight (B) 24 h] 24 h] 24 h] (B)/(A)} Example 6 IMQ 3 120 0.012 2 — 167 Example 7 LOX 3 120 0.015 — 42 2800 Example 8 IMQ 0.05 25 — — — 625 Comparative IMQ 0.05 25 — — — 125 Example 7 Comparative IMQ 0.05 25 — — — 25 Example 8 Comparative IMQ 0.05 25 — — — 0.3 Example 9 Example 9 LOX 0.05 25 — — — 3125 Example 10 LOX 0.05 25 — — — 625 Comparative LOX 0.05 25 — — — 125 Example 10 Comparative LOX 0.05 25 — — — 25 Example 11 Comparative LOX 0.05 25 — — — 0.3 Example 12 indicates data missing or illegible when filed

TABLE-US-00005 TABLE 4 Second First cellular cellular immunity immunity induction induction promoter promoter (helper (other than Antigen peptide peptide) helper peptide) % by Dose % by % by Dose Route Base Kind weight (ug) (A) Kind weight Kind weight (ug) (B) Example 11 Transdermal Cream PR1 peptide 5 200 PADRE 1 IMQ 3 120 Example 12 Injection Saline/Montanide PR1 peptide 0.00008 0.04 PADRE 0.05 IMQ 0.05 25 Comparative (subcutaneous) Saline/Montanide PR1 peptide 0.0004 0.2 PADRE 0.05 IMQ 0.05 25 Example 13 Comparative Saline/Montanide PR1 peptide 0.002 1 PADRE 0.05 IMQ 0.05 25 Example 14 Comparative Saline/Montanide PR1 peptide 0.2 100 PADRE 0.05 IMQ 0.05 25 Example 15

TABLE-US-00006 TABLE 5 Second First cellular cellular immunity immunity induction induction promoter promoter (helper (other than Antigen peptide peptide) helper peptide) % by Dose % by % by Dose Route Base Kind weight (ug) (A) Kind weight Kind weight (ug) (B) Example 13 Transdermal Cream HER2/neu_E75 5 200 PADRE 1 IMQ 3 120 peptide Example 14 Injection Saline/ HER2/neu_E75 0.00008 0.04 PADRE 0.05 IMQ 0.05 25 (subcutaneous) Montanide peptide Comparative Saline/ HER2/neu_E75 0.0004 0.2 PADRE 0.05 IMQ 0.05 25 Example 16 Montanide peptide Comparative Saline/ HER2/neu_E75 0.002 1 PADRE 0.05 IMQ 0.05 25 Example 17 Montanide peptide Comparative Saline/ HER2/neu_E75 0.2 100 PADRE 0.05 IMQ 0.05 25 Example 18 Montanide peptide

TABLE-US-00007 TABLE 6 Second First cellular cellular immunity immunity induction induction promoter promoter (helper (other than Antigen peptide peptide) helper peptide) % by Dose % by % by Dose Route Base Kind weight (ug) (A) Kind weight Kind weight (ug) (B) Example 15 Transdermal Cream Survivin 2B 5 200 PADRE 1 IMQ 3 120 peptide Example 16 Injection Saline/ Survivin 2B 0.00008 0.04 PADRE 0.05 IMQ 0.05 25 (subcutaneous) Montanide peptide Comparative Saline/ Survivin 2B 0.0004 0.2 PADRE 0.05 IMQ 0.05 25 Example 19 Montanide peptide Comparative Saline/ Survivin 2B 0.002 1 PADRE 0.05 IMQ 0.05 25 Example 20 Montanide peptide Comparative Saline/ Survivin 2B 0.2 100 PADRE 0.05 IMQ 0.05 25 Example 21 Montanide peptide

INDUSTRIAL APPLICABILITY

[0414] The vaccine pharmaceutical composition of the present invention can be universally used for induction of cellular immunity to various antigens and exerts a high cellular immunity inducing effect. The vaccine pharmaceutical composition effectively exerts a cellular immunity inducing effect even in continuous multiple dose administration.

SEQUENCE LISTING FREE TEXT

[0415]